This paper investigated if extracting microRNA (miRNA, miR) from plasma precipitates rather than plasma improves discrimination between patients with breast cancer and healthy controls.
Improved Discrimination of Patients with Breast Cancer from Healthy Controls Using Paper-Based microRNA Expression Profiling of Plasma, Following Precipitation.
Tan KML, Tay SP, Chua HW, Sufyan Bin Masroni M, Tucker S, Koay ES, Leong SM
Purpose
Conclusion
miRNA levels in precipitates provided better discrimination between breast cancer patients and healthy controls than plasma. Levels of miR-16, miR-106b, and miR-486-5p were significantly higher in breast cancer patients than healthy controls.s.
Studies (1)
Purpose
This study investigated if extracting miRNA from plasma precipitates rather than plasma improves discrimination between patients with breast cancer and healthy controls. Peripheral blood from 9 healthy controls and 9 patients with breast cancer was centrifuged at 3000 x g for 10 min to obtain plasma. Plasma was stored at -80˚C and visually inspected to confirm the absence of hemolysis. RNA was extracted directly from plasma using the FTA Elute MicroCard. To investigate the effect of precipitation, Total Exosome Isolation reagent was added to plasma and the specimen was vortexed and centrifuged at 10000 x g for 10 min. The pellet was resuspended in PBS, spotted on an FTA Elute MicroCard, and then the card was washed in 70% ethanol. RNA was eluted with DEPC water and miRNAs were quantified using the real-time PCR MiRXES IDEAL miRNA assays. Values were normalized to the mean quantification cycle (Cq) value for all miRNA.
Summary of Findings
Plasma precipitates from breast cancer patients had significantly higher levels of miR-16 (P=0.0020), miR-106b (P=0.0135), and miR-486-5p (P=0.0047) than precipitates from healthy controls. Plasma showed more overlap in Cq values between breast cancer patients and controls than what was observed from precipitates, but plasma from breast cancer patients had significantly higher levels of miR-16 (P=0.0244), miR-106b (P=0.0424), and miR-486-5p (P=0.0173) than healthy controls. Principle component analysis confirmed better discrimination between breast cancer patients and controls in precipitates than plasma. The precipitates had a larger area under the receiver operator curves (AUROC) than plasma for all four miRNAs examined.
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
NormalNeoplasticCarcinomaPlatforms
RNAReal-time qRT-PCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Breast cancerHealthyBiospecimen Aliquots and Components Blood and blood products PlasmaPlasma precipitatesReal-time qRT-PCR Specific Targeted nucleic acid miR-106bmiR-16miR-222miR-486-5p